At the news
? BULLISHIMPACT 8/10 6-K filed Apr 21, 2026 at 06:19 ET
AstraZeneca announced positive interim results from the Phase III I CAN trial, showing that Ultomiris (ravulizumab) met its primary endpoint with a statistically significant and clinically meaningful reduction in proteinuria in adults with immunoglobulin A nephropathy (IgAN). The company plans to seek accelerated approval in key markets and present full results at a future medical meeting.
- Ultomiris met the primary endpoint of statistically significant and clinically meaningful reduction in proteinuria (measured by 24-hour UPCR) at week 34 in the I CAN Phase III trial.
- The trial enrolled approximately 510 adults with IgAN at risk of disease progression across 28 countries.
- Ultomiris demonstrated rapid reduction in proteinuria as early as week 10.
- The safety profile was consistent with known data, with no new safety concerns.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access